Bank of New York Mellon’s Quince Therapeutics QNCX Stock Holding History

Bank of New York Mellon’s Portfolio QNCX Stock Details QNCX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-446	Closed	-$552K	–	4679
2022 Q1	$552K	Hold	446	–	–	﹤0.01%	3648
2021 Q4	$1.13M	Buy	446 +139	+45%	+$848K	﹤0.01%	3318
2021 Q3	$5.62M	Buy	307 +30	+11%	+$477K	﹤0.01%	2426
2021 Q2	$2.93M	Sell	277 -19	-6%	-$159K	﹤0.01%	2768
2021 Q1	$2.13M	Sell	296 -8	-3%	-$57.6K	﹤0.01%	2893
2020 Q4	$1.69M	Sell	304 -80	-21%	-$709K	﹤0.01%	2944
2020 Q3	$3.84M	Buy	384 +3	+0.8%	+$27.3K	﹤0.01%	2356
2020 Q2	$3.53M	Buy	381 +107	+39%	+$980K	﹤0.01%	2380
2020 Q1	$2.5M	Buy	274 +80	+41%	+$790K	﹤0.01%	2443
2019 Q4	$2.18M	Buy	194 +125	+181%	+$754K	﹤0.01%	2774
2019 Q3	$345K	Buy	69 +28	+68%	+$172K	﹤0.01%	3724
2019 Q2	$349K	Buy	+41	New	+$245K	﹤0.01%	3753

Other funds holding QNCX

ECG

EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

PHAM

Pacific Heights Asset Management San Francisco, California $2.99B AUM 52.5% 1-Year Est. Return

Bank of New York Mellon's QNCX Position: Q2 2022 in Review

Bank of New York Mellon sold out of Quince Therapeutics (QNCX) in Q2 2022, closing a stake of 446 shares — an estimated $552K sold.

Bank of New York Mellon first reported a position in QNCX in Q2 2019 and held it in 12 quarters. The position peaked at $5.62M in Q3 2021. 66 funds tracked by Wall St. Rank hold QNCX as of Q2 2022.

Bank of New York Mellon reported no remaining Quince Therapeutics position as of Q2 2022 after selling out during the quarter.
Bank of New York Mellon sold 446 Quince Therapeutics shares in Q2 2022, an estimated $552K.
Bank of New York Mellon first reported a position in Quince Therapeutics in Q2 2019 and held it in 12 quarters.
Bank of New York Mellon's Quince Therapeutics position peaked at $5.62M in Q3 2021.
66 funds tracked by Wall St. Rank held Quince Therapeutics as of Q2 2022.

Based on Bank of New York Mellon's 13F filing for Q2 2022, filed 15 Aug 2022.